[1] Camplesi M Junior, Silva HM, Arantes AM, et al.Invasive fungal infection in patients with hematologic disorders in a Brazilian tertiary care hospital[J]. Rev Soc Bras Med Trop,2017,50(1):80-85. [2] Perlroth J, Choi B, Spellberg B.Nosocomial fungal infections: epidemiology, diagnosis, and treatment[J]. Med Mycol,2007,45(4):321-346. [3] Wang H, Xiao M, Chen SC, et al.In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study[J]. J Clin Microbiol,2012,50(12):3952-3959. [4] Sanglard D.Emerging Threats in Antifungal-Resistant Fungal Pathogens[J]. Front Med (Lausanne),2016,3:11. [5] Versalovic J, Koeuth T, Lupski JR.Distribution of repeti-tive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes[J]. Nucleic Acids Res,1991,19(24):6823-6831. [6] Rex JH, Walsh TJ, Sobel JD, et al.Practice guidelines for the treatment of candidiasis. Infectious Diseases Socie-ty of America[J]. Clin Infect Dis,2000,30(4):662-678. [7] Cantón E, Pemán J, Quindós G, et al.Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia[J]. Antimicrob Agents Chemother,2011,55(12):5590-5596. [8] Cleveland AA, Farley MM, Harrison LH, et al.Changes in incidence and antifungal drug resistance in candide-mia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011[J]. Clin Infect Dis,2012,55(10):1352-1361. [9] Pfaller MA, Jones RN, Castanheira M.Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011[J]. Mycoses,2014,57(10):602-611. [10] Bennett JE, Izumikawa K, Marr KA.Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis[J]. Antimicrob Agents Chemother,2004,48(5):1773-1777. [11] Sanguinetti M, Posteraro B, Fiori B, et al.Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance[J]. Antimicrob Agents Chemother,2005,49(2):668-679. [12] Torelli R, Posteraro B, Ferrari S, et al.The ATP-binding cassette transporter-encoding gene CgSNQ2 is contribu-ting to the CgPDR1-dependent azole resistance of Candida glabrata[J]. Mol Microbiol,2008,68(1):186-201. [13] Ferrari S, Ischer F, Calabrese D, et al.Gain of function mutations in CgPDR1 of Candida glabrata not only media-te antifungal resistance but also enhance virulence[J]. PLoS Pathog,2009,5(1):e1000268. [14] Shin JH, Chae MJ, Song JW, et al.Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia[J]. J Clin Microbiol,2007,45(8):2385-2391. [15] Souza AC, Fuchs BB, Pinhati HM, et al.Candida parapsilosis resistance to fluconazole: molecular mechanisms and in vivo impact in infected Galleria mellonella Larvae[J]. Antimicrob Agents Chemother,2015,59(10):6581-6587. [16] Zhang L, Xiao M, Watts MR, et al.Development of fluconazole resistance in a series of Candida parapsilosis isolates from a persistent candidemia patient with prolonged antifungal therapy[J]. BMC Infect Dis,2015,15:340. [17] Silva AP, Miranda IM, Guida A, et al.Transcriptional profiling of azole-resistant Candida parapsilosis strains[J]. Antimicrob Agents Chemother,2011,55(7):3546-3556. [18] Branco J, Silva AP, Silva RM, et al.Fluconazole and voriconazole resistance in Candida parapsilosis Is conferred by gain-of-function mutations in MRR1 transcription factor gene[J]. Antimicrob Agents Chemother,2015, 59(10):6629-6633. |